PDC-1421 Treatment in Adult Patients With ADHD

Summary

Part II is a double-blind, randomized, parallel-group, placebo-controlled study. The primary objective of this trial is to determine the effective doses and treatment period of PDC-1421 Capsule in subjects with ADHD. The secondary objective is to evaluate the safety of PDC-1421 Capsule in subjects receiving PDC-1421 at various dose levels.

Timeline

Start

2022-04-07

Primary completion

2023-12-06

Completion

2024-04-08

Drugs

Indications